Home › Companies › BRIDGEBIO PHARMA INC. › 2023-2024

BRIDGEBIO PHARMA INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and BRIDGEBIO PHARMA INC.’s Form 8-K, filed 2024-06-24 (Item 5.07 on EDGAR). Page generated 02 October 2026.

9Reported items
286Asset managers
2,615Fund votes
2024-06-21Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BRIDGEBIO PHARMA INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by BRIDGEBIO PHARMA INC.

These tallies are BRIDGEBIO PHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-24 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BRIDGEBIO PHARMA INC. — official shareholder meeting results, meeting held 2024-06-21
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Eric Aguiar, M.D.	139,080,658	--	--	4,552,096	--	Majority: yes
Elect Director: Jennifer E. Cook	139,063,404	--	--	4,569,350	--	Majority: yes
Elect Director: Andrea J. Ellis	139,229,888	--	--	4,402,866	--	Majority: yes
Elect Director: Fred Hassan	137,076,192	--	--	6,556,562	--	Majority: yes
Elect Director: Ali J. Satvat	106,237,448	--	--	37,395,306	--	Majority: yes

Source: BRIDGEBIO PHARMA INC., Form 8-K, filed with the SEC on 2024-06-24 — read the filing on EDGAR.

How asset managers voted at the BRIDGEBIO PHARMA INC. 2023-2024 meeting

Each item below shows how the 286 asset managers that disclosed a BRIDGEBIO PHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BRIDGEBIO PHARMA INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 12 wordings of this item as funds reported it.

92% fund support · no official result

FOR 92%8%

The 277 asset managers below cast 92% of the shares they voted on this item FOR (139,978,351 for, 12,810,120 against).

FOR: 139,978,351 (91.6%)AGAINST: 12,810,120 (8.4%)ABSTAIN: 23,228 (0.0%)

Largest asset managers voting on “To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Against	Vote
Kohlberg Kravis Roberts & Co. L.P.	31,060,971	0	For
VIKING GLOBAL INVESTORS LP	25,120,991	0	For
Vanguard	13,791,484	0	For
State Street	7,610,290	1,320	For
Fidelity	6,905,580	36,680	For
BlackRock	6,827,770	18,660	For
Aisling Capital Management LP	6,068,125	0	For
T. Rowe Price	3,768,984	0	For
AllianceBernstein	0	3,501,820	Against
Laurion Capital Management LP	3,450,031	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,772,235	0	For
PICTET ASSET MANAGEMENT SA	2,276,346	0	For
Charles Schwab	2,133,851	0	For
Janus Henderson	2,076,340	0	For
Invesco	0	1,532,349	Against
American Century	0	1,430,487	Against
HHLR ADVISORS, LTD.	1,367,489	0	For
Cormorant Asset Management, LP	1,317,824	0	For
Ensign Peak Advisors, Inc	1,259,213	0	For
Wellington	0	1,253,589	Against
John Hancock	1,137,053	60,996	For
JANUS INVESTMENT FUND	1,144,213	0	For
Capital Research Global Investors	1,111,975	0	For
LORD, ABBETT & CO. LLC	1,039,049	0	For
PRIMECAP MANAGEMENT CO/CA/	927,230	0	For

Showing the 25 largest of 277 asset managers. See all 277 in the interactive database.

2. To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares.

COMPENSATION

Combines 3 wordings of this item as funds reported it.

81% fund support · no official result

FOR 81%AGAINST 19%

The 91 asset managers below cast 81% of the shares they voted on this item FOR (32,696,409 for, 7,439,544 against).

FOR: 32,696,409 (81.4%)AGAINST: 7,439,544 (18.5%)ABSTAIN: 23,210 (0.1%)

Largest asset managers voting on “To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option a” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	13,498,499	0	For
Fidelity	4,812,797	0	For
BlackRock	3,568,991	0	For
State Street	2,650,477	3,649	For
T. Rowe Price	983,540	593,183	For
JANUS INVESTMENT FUND	709,678	434,535	For
Charles Schwab	0	1,052,317	Against
AllianceBernstein	996,947	0	For
Lord Abbett	0	921,378	Against
Principal	403,425	345,388	For
American Century	0	684,204	Against
NEW ECONOMY FUND	674,110	0	For
Invesco	671,916	0	For
PRIMECAP Odyssey Funds	630,030	0	For
MUTUAL FUND SERIES TRUST	579,414	0	For
AB DISCOVERY GROWTH FUND, INC.	559,061	0	For
Equitable	511,003	0	For
Capital Group	413,794	0	For
Victory Capital	0	384,540	Against
MFS	0	376,756	Against
TIAA	0	303,278	Against
Jackson National	0	264,398	Against
FINANCIAL INVESTORS TRUST	242,995	0	For
Direxion Shares ETF Trust	0	214,737	Against
Hartford	0	202,784	Against

Showing the 25 largest of 91 asset managers. See all 91 in the interactive database.

3. To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 89 asset managers below cast 100% of the shares they voted on this item FOR (39,960,453 for, 0 against).

FOR: 39,960,453 (99.9%)ABSTAIN: 23,210 (0.1%)

Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Vote
Vanguard	13,498,499	For
Fidelity	4,812,797	For
BlackRock	3,568,991	For
State Street	2,654,126	For
T. Rowe Price	1,576,723	For
JANUS INVESTMENT FUND	1,144,213	For
Charles Schwab	1,052,317	For
AllianceBernstein	996,947	For
Lord Abbett	921,378	For
Principal	748,813	For
American Century	684,204	For
NEW ECONOMY FUND	674,110	For
Invesco	671,916	For
PRIMECAP Odyssey Funds	630,030	For
MUTUAL FUND SERIES TRUST	579,414	For
AB DISCOVERY GROWTH FUND, INC.	559,061	For
Equitable	511,003	For
Capital Group	413,794	For
Victory Capital	384,540	For
MFS	376,756	For
TIAA	303,278	For
Jackson National	264,398	For
FINANCIAL INVESTORS TRUST	242,995	For
Direxion Shares ETF Trust	214,737	For
Hartford	202,784	For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

4. To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Eric Aguiar, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 139,080,658WITHHELD: 4,552,096

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Eric Aguiar, M.D.”): 139,080,658 for, 4,552,096 withheld, per its Form 8-K filed 2024-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 187,122,744 outstanding shares: 74% for, 2% withheld (77% of the company cast a for/withheld vote).

The 88 asset managers below cast 100% of the shares they voted on this item FOR (37,265,885 for, 0 against).

FOR 93%

FOR: 37,265,885 (93.2%)ABSTAIN: 2,716,308 (6.8%)

Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	13,498,499	0	For
Fidelity	4,776,117	36,680	For
BlackRock	3,568,991	0	For
State Street	2,653,842	284	For
T. Rowe Price	1,576,723	0	For
JANUS INVESTMENT FUND	1,144,213	0	For
Charles Schwab	1,052,317	0	For
AllianceBernstein	0	996,947	Abstain
Lord Abbett	921,378	0	For
Principal	345,388	403,425	Abstain
American Century	684,204	0	For
NEW ECONOMY FUND	674,110	0	For
Invesco	671,916	0	For
PRIMECAP Odyssey Funds	630,030	0	For
MUTUAL FUND SERIES TRUST	579,414	0	For
AB DISCOVERY GROWTH FUND, INC.	0	559,061	Abstain
Equitable	179,376	331,627	Abstain
Capital Group	413,794	0	For
Victory Capital	384,540	0	For
MFS	376,756	0	For
TIAA	303,278	0	For
Jackson National	264,398	0	For
FINANCIAL INVESTORS TRUST	0	242,995	Abstain
Direxion Shares ETF Trust	214,737	0	For
Hartford	202,784	0	For

Showing the 25 largest of 88 asset managers. See all 88 in the interactive database.

5. To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Ali J. Satvat

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 106,237,448WITHHELD: 37,395,306

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Ali J. Satvat”): 106,237,448 for, 37,395,306 withheld, per its Form 8-K filed 2024-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 187,122,744 outstanding shares: 57% for, 20% withheld (77% of the company cast a for/withheld vote).

The 87 asset managers below cast 99.9% of the shares they voted on this item FOR (23,958,343 for, 144 against).

FOR 61%ABSTAIN 39%

FOR: 23,958,343 (60.8%)AGAINST: 144 (0.0%)ABSTAIN: 15,444,292 (39.2%)

Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	13,498,499	0	For
Fidelity	4,723,513	89,284	For
BlackRock	0	3,568,991	Abstain
State Street	2,742	2,651,384	Abstain
T. Rowe Price	1,576,723	0	For
JANUS INVESTMENT FUND	709,678	434,535	For
Charles Schwab	1,052,317	0	For
AllianceBernstein	0	996,947	Abstain
Lord Abbett	0	921,378	Abstain
Principal	0	748,813	Abstain
American Century	0	684,204	Abstain
NEW ECONOMY FUND	674,110	0	For
Invesco	0	671,916	Abstain
PRIMECAP Odyssey Funds	630,030	0	For
AB DISCOVERY GROWTH FUND, INC.	0	559,061	Abstain
Equitable	0	511,003	Abstain
Capital Group	413,794	0	For
Victory Capital	994	383,546	Abstain
MFS	0	376,756	Abstain
TIAA	0	303,278	Abstain
Jackson National	93,551	170,847	Abstain
FINANCIAL INVESTORS TRUST	0	242,995	Abstain
Direxion Shares ETF Trust	0	214,737	Abstain
Hartford	202,784	0	For
Bridge Builder Trust	0	150,858	Abstain

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

6. To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Andrea J. Ellis

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 139,229,888WITHHELD: 4,402,866

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Andrea J. Ellis”): 139,229,888 for, 4,402,866 withheld, per its Form 8-K filed 2024-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 187,122,744 outstanding shares: 74% for, 2% withheld (77% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (36,686,471 for, 0 against).

FOR 93%

FOR: 36,686,471 (93.1%)ABSTAIN: 2,716,308 (6.9%)

Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	13,498,499	0	For
Fidelity	4,776,117	36,680	For
BlackRock	3,568,991	0	For
State Street	2,653,842	284	For
T. Rowe Price	1,576,723	0	For
JANUS INVESTMENT FUND	1,144,213	0	For
Charles Schwab	1,052,317	0	For
AllianceBernstein	0	996,947	Abstain
Lord Abbett	921,378	0	For
Principal	345,388	403,425	Abstain
American Century	684,204	0	For
NEW ECONOMY FUND	674,110	0	For
Invesco	671,916	0	For
PRIMECAP Odyssey Funds	630,030	0	For
AB DISCOVERY GROWTH FUND, INC.	0	559,061	Abstain
Equitable	179,376	331,627	Abstain
Capital Group	413,794	0	For
Victory Capital	384,540	0	For
MFS	376,756	0	For
TIAA	303,278	0	For
Jackson National	264,398	0	For
FINANCIAL INVESTORS TRUST	0	242,995	Abstain
Direxion Shares ETF Trust	214,737	0	For
Hartford	202,784	0	For
Bridge Builder Trust	150,858	0	For

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

7. To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Fred Hassan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 137,076,192WITHHELD: 6,556,562

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Fred Hassan”): 137,076,192 for, 6,556,562 withheld, per its Form 8-K filed 2024-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 187,122,744 outstanding shares: 73% for, 4% withheld (77% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (36,286,126 for, 0 against).

FOR 92%8%

FOR: 36,286,126 (92.1%)ABSTAIN: 3,116,653 (7.9%)

Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	13,498,499	0	For
Fidelity	4,776,117	36,680	For
BlackRock	3,568,991	0	For
State Street	2,653,842	284	For
T. Rowe Price	1,576,723	0	For
JANUS INVESTMENT FUND	1,144,213	0	For
Charles Schwab	1,052,317	0	For
AllianceBernstein	0	996,947	Abstain
Lord Abbett	921,378	0	For
Principal	345,388	403,425	Abstain
American Century	684,204	0	For
NEW ECONOMY FUND	674,110	0	For
Invesco	671,916	0	For
PRIMECAP Odyssey Funds	630,030	0	For
AB DISCOVERY GROWTH FUND, INC.	0	559,061	Abstain
Equitable	179,376	331,627	Abstain
Capital Group	413,794	0	For
Victory Capital	383,546	994	For
MFS	376,756	0	For
TIAA	303,278	0	For
Jackson National	264,398	0	For
FINANCIAL INVESTORS TRUST	0	242,995	Abstain
Direxion Shares ETF Trust	214,737	0	For
Hartford	0	202,784	Abstain
Bridge Builder Trust	150,858	0	For

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

8. To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Jennifer E. Cook

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 139,063,404WITHHELD: 4,569,350

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Jennifer E. Cook”): 139,063,404 for, 4,569,350 withheld, per its Form 8-K filed 2024-06-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 187,122,744 outstanding shares: 74% for, 2% withheld (77% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (36,686,471 for, 0 against).

FOR 93%

FOR: 36,686,471 (93.1%)ABSTAIN: 2,716,308 (6.9%)

Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	13,498,499	0	For
Fidelity	4,776,117	36,680	For
BlackRock	3,568,991	0	For
State Street	2,653,842	284	For
T. Rowe Price	1,576,723	0	For
JANUS INVESTMENT FUND	1,144,213	0	For
Charles Schwab	1,052,317	0	For
AllianceBernstein	0	996,947	Abstain
Lord Abbett	921,378	0	For
Principal	345,388	403,425	Abstain
American Century	684,204	0	For
NEW ECONOMY FUND	674,110	0	For
Invesco	671,916	0	For
PRIMECAP Odyssey Funds	630,030	0	For
AB DISCOVERY GROWTH FUND, INC.	0	559,061	Abstain
Equitable	179,376	331,627	Abstain
Capital Group	413,794	0	For
Victory Capital	384,540	0	For
MFS	376,756	0	For
TIAA	303,278	0	For
Jackson National	264,398	0	For
FINANCIAL INVESTORS TRUST	0	242,995	Abstain
Direxion Shares ETF Trust	214,737	0	For
Hartford	202,784	0	For
Bridge Builder Trust	150,858	0	For

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

9. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

99.6% fund support · no official result

FOR 99.6%

The 5 asset managers below cast 99.6% of the shares they voted on this item FOR (399,061 for, 1,407 against).

FOR: 399,061 (99.6%)AGAINST: 1,407 (0.4%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at BRIDGEBIO PHARMA INC., 2023-2024
Asset manager	For	Against	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	299,000	0	For
JPMorgan	79,260	0	For
APG Asset Management US Inc.	20,801	0	For
ALGERT GLOBAL LLC	0	757	Against
Desjardins Global Asset Management Inc.	0	650	Against

Largest BRIDGEBIO PHARMA INC. shareholders voting in 2023-2024

Ranked by the number of BRIDGEBIO PHARMA INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 187,122,744 shares outstanding at the time of that meeting.

Top BRIDGEBIO PHARMA INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Kohlberg Kravis Roberts & Co. L.P.	16.60%
2	VIKING GLOBAL INVESTORS LP	13.42%
3	Vanguard	7.37%
4	State Street	4.07%
5	Fidelity	3.71%
6	BlackRock	3.66%
7	Aisling Capital Management LP	3.24%
8	T. Rowe Price	2.01%
9	AllianceBernstein	1.87%
10	Laurion Capital Management LP	1.84%

Reported BRIDGEBIO PHARMA INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BRIDGEBIO PHARMA INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Ali J. Satvat	16.82%	DEF14A
KKR Genetic Disorder L.P.	16.60%	DEF14A
Viking Global Entities	13.42%	DEF14A
Vanguard Group	9.00%	13F
BlackRock	7.70%	13F
Neil Kumar, Ph.D.	5.41%	DEF14A
State Street	2.88%	13F
Geode Capital	1.53%	13F
Goldman Sachs	1.24%	13F
Charles Homcy, M.D.	0.96%	DEF14A

Percentages above are of 187,122,744 shares outstanding, as reported by BRIDGEBIO PHARMA INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BRIDGEBIO PHARMA INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At BRIDGEBIO PHARMA INC.'s shareholder meeting held 2024-06-21, in the 2023-2024 proxy season, 286 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,615 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. BRIDGEBIO PHARMA INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To cast a non-binding, advisory vote to approve the compensation of the Company's named… — the reporting funds cast 92% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

BRIDGEBIO PHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.